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Received May 7, 2011; accepted March 15, 2012AbstractHepatic veno-occlusive disease (HVOD) describes the nonthrombotic, fibrous obliteration of the small centrilobular hepatic veins by con-
nective tissue and centrilobular necrosis in zone 3 of the acini. Occlusion of the terminal venules of the liver might result in HVOD with the
characteristic clinical findings of painful hepatomegaly, ascites, jaundice, and weight gain for more than 5% of patients. It is mainly observed
after hematopoietic stem cell transplantation (SCT) and is responsible for significant morbidity and mortality. The incidence of HVOD is much
lower after solid organ transplantation than after SCT and seems to differ from one organ to another. It has been sporadically reported after lung,
renal, and liver transplantation, but has never been reported after pancreas transplantation. In general, HVOD is presumably attributed to
azathioprine or tacrolimus used in solid organ transplantation. Here we describe a case of HVOD occurring after pancreas transplantation, in
which tacrolimus might have played a causative role because complete recovery was observed after discontinuation of tacrolimus. Pancreas
transplantation physicians should raise the suspicion of HVOD when a recipient presents with hepatomegaly, ascites, or jaundice.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Hepatic veno-occlusive disease (HVOD) is a distinct clin-
ical entity describing the nonthrombotic, fibrous obliteration
of the small centrilobular hepatic veins by connective tissue
and centrilobular necrosis in zone 3 of the acini.1e3 Based on
recent work suggesting that sinusoidal changes are primary
events in the pathology of the disease, the term sinusoidal
obstruction syndrome is considered to better describe the
condition.4 Occlusion of the terminal venules of the liver
might result in HVOD with the characteristic clinical findings
of painful hepatomegaly, ascites, jaundice, and weight gain in
more than 5% of patients.2e8* Corresponding author. Dr. Yi-Ming Shyr, Division of General Surgery,
Department of Surgery, Taipei Veterans General Hospital, 201, Section 2,
Shih-Pai Road, Taipei 112, Taiwan, ROC.
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http://dx.doi.org/10.1016/j.jcma.2013.03.001HVOD was first described in Jamaicans who had consumed
large amounts of Senecio plants in the form of “bush tea”
containing pyrrolizidine alkaloids.2 This disease is also well
known to be associated with Mylotarg, a monoclonal anti-
CD33 antibody gemtuzumab ozogamicin used for acute my-
elogenous leukemia, and is now mainly observed in patients
with hematopoietic stem cell transplantation (SCT) following
the administration of various chemotherapeutic agents such as
actinomycin D, mithramycin, dacarbazine, cytosine arabino-
side, and 6-thioguanine.2,3 However, HVOD has also been
reported after solid organ transplantation, but much less
frequently. In general, the disease is presumably attributed to
azathioprine2,9e12 or tacrolimus1,6 used in solid organ trans-
plantation. Cases have been sporadically described after
lung,1,6 renal,2,9e13 and liver4e18 transplantation, but have
never been reported in the literature after pancreas trans-
plantation. Here, we report a case of HVOD occurring after
pancreas transplantation, in which tacrolimus might have
played a causative role.hinese Medical Association. All rights reserved.
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A 25-year-old female began to suffer from type 2 diabetes
mellitus at the age of 11 years and had experienced uremia
under hemodialysis for 3 years. She underwent simultaneous
pancreas and kidney transplantation on June 30, 2009, with
one mismatch for human leukocyte antigen typing and 84.5%
panel reactive antibody level for Class I and 31.84% for Class
II, but a negative pretransplant lymphocytotoxic crossmatch.
Unfortunately, primary nonfunction of the kidney graft
occurred because of a technical complication with the occlu-
sion of the renal artery, and the failed kidney graft was
explanted on postoperative day 1. Immunosuppressive therapy
included basiliximab (Simulect, Novartis Pharmaceuticals
Corporation, East Hanover, NJ, USA) for induction (given on
postoperative day 0 and day 4), and tacrolimus (Prograf,
Astellas Pharma US, Inc., Deerfield, IL, USA), Myfortic
(enteric-coated mycophenolic acid; Novartis Pharmaceuticals
Corporation, East Hanover, NJ, USA), and prednisolone for
maintenance therapy. Prednisolone was tapered and withdrawn
completely 3 months after transplantation. The target trough
level for tacrolimus was 6e15 ng/mL.
Approximately 9 months after transplantation, this patient
reported development of fever, mild right abdominal pain, and
an increase in abdominal girth. The fever subsided spontane-
ously without known cause. The pancreas graft had been
functioning well without evidence of rejection or pancreatitis
(fasting blood sugar: 85 mg/dL, c-peptide: 9.79 ng/mL,
amylase: 85 U/L, lipase: 22 U/L). The laboratory data showed
leukopenia (1600/mm3) and thrombocytopenia (8900/mm3).
The computed tomography (CT) scan showed pictures of
HVOD with hepatomegaly, massive ascites, periportal edema,
diffuse mottled hepatic enhancement, and patent hepatic veins
(Fig. 1). The periportal edema and diffuse mottled hepatic
enhancement, in addition to the signs of portal hypertension,
might have suggested sinusoidal stasis. The inferior vena cava
was patent by CT scan. There was no evidence of heart failure
by chest X-ray image study and clinical feature. An initial
liver biopsy attempt was aborted owing to significantFig. 1. A 25-year-old female with hepatic veno-occlusive disease after pancreas tran
images shows (A) a normal homogenous enhancement of the liver and a pancreas
head-up position 2 weeks after pancreas transplant; (B) hepatomegaly, ascites, perip
stasis with patent hepatic veins and gallbladder edema (not shown) about 8 months a
homogenous 3 months after tacrolimus was discontinued and replaced by cyclospcoagulopathy and massive ascites. Meanwhile, a massive
bloody stool occurred during hospitalization. The angiography
showed a pseudoaneurysm with bleeding from a branch of the
ileocolic artery. The cause of the pseudoaneurysm was not
known, but did not seem to be related to the HVOD. The
bleeding was eventually stopped by transarterial embolization
and correction of the coagulopathy.
Tacrolimus was discontinued and replaced by cyclosporine
(Novartis Pharmaceuticals Corporation) with a target trough
level of 200e300 ng/mL. Otherwise, no alternation of other
medications was made. Three months after discontinuing
tacrolimus, there was resolution of the patient HVOD
demonstrated by CT scan (Fig. 1C). All the blood cell counts
also returned to normal level. These observations might lead to
the conclusion that tacrolimus could be the causative agent for
HVOD in this case.
3. Discussion
HVOD is mainly observed after hematopoietic SCT and
may be responsible for significant morbidity and mortality.
The incidence of HVOD after hematopoietic SCT is variable,
ranging from 10% to 60%.4,5 The number of reported HVOD
cases after solid organ transplantation is rather low, and most
of them are sporadically reported, with an incidence of
1.9e2.5% after kidney transplantation, and HVOD cases seem
to differ from one organ to another.1,2,6,9 In these reports,
HVOD is generally linked to the administration of
azathioprine.2,10e12 Tacrolimus, a calcinurin inhibitor, is
currently one of the most common potent immunosuppressants
used in organ transplantations. Although tacrolimus undergoes
hepatic metabolism, only mild hepatotoxicity has been re-
ported with its use. Nevertheless, HVOD induced by tacroli-
mus has also been reported, but less commonly as compared to
that by azathioprine.1
The classical characteristics of painful hepatomegaly, as-
cites, jaundice, and weight gain for more than 5% of patients
has been described in HVOD,2e8 but the clinical diagnosis of
HVOD is usually difficult because the symptoms and signs ofsplant. Post contrast-enhanced coronal reformatted computed tomography (CT)
graft surrounded by a small amount of fluid in the right lower abdomen with
ortal edema, and diffuse mottled hepatic enhancement suggestive of sinusoidal
fter pancreas transplant; and (C) hepatic parenchymal enhancement returned to
orine.
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states.1,4,5 As shown in our case, an abdominal CT showing
periportal edema and diffuse mottled hepatic enhancement, in
addition to the signs of portal hypertension, might suggest the
occlusive patterns of small centrilobular hepatic veins and
could lead to the diagnosis of HVOD for transplant patients at
risk. Some authors claimed that a hepatic ultrasound showing
the detection of reversed blood flow in the segmental branch of
the portal vein using color flow Doppler may be also helpful in
the diagnosis of HVOD.2,3 For clinically suspected cases, liver
biopsy for histological examination would be the gold stan-
dard to confirm the diagnosis. Liver biopsies may reveal
dilated sinusoids and hepatic necrosis with sclerosis of the
venular walls and intense collagen deposition in the sinusoids,
which eventually lead to obliteration of the venules, extensive
hepatocellular necrosis, and fibrous replacement of the hepatic
tissue.1,4,5 The reason that a percutaneous liver biopsy is not
always suitable for patients with HVOD is because most of
them present with ascites and the associated hemostatic dis-
orders, as in our case. Therefore, the liver biopsy could be
done by transjugular approach. Meanwhile, a measurement of
the wedged hepatic venous pressure gradient of 10 mmHg
taken at the time of the transjugular biopsy provides additional
clues and has a 91% specificity, 52% sensitivity, and 86%
positive predictive value in the diagnosis of HVOD.5
Currently, little information is available on the treatment of
HVOD. Several approaches have been tried, but none is uni-
formly effective. Nevertheless, as shown in our case, early
withdrawal of causative immunosuppressants such as azathi-
oprine and tacrolimus seem to be the key.1,2,6 The lack of an
effective therapy for HVOD has spurred much interest in
finding potential medications to prevent the disease, such as
low-molecular-weight heparin, ursodeoxycholic acid, and
pentoxifylline (a xanthine derivative).2 Prognosis depends on
the severity of hepatic injury and dysfunction. Mild disease is
defined by no significant adverse effect from liver dysfunction
and is often self-limited and resolves without treatment after
the offending agent is withdrawn. Moderate disease is char-
acterized by liver dysfunction requiring therapy for control of
symptoms such as diuresis for abdominal distension due to
fluid retention and analgesia for pain due to hepatomegaly, but
with eventual complete resolution. By contrast, while most
patients with HVOD fall into the mild to moderate category, a
significant fraction will develop severe HVOD characterized
by a nonresolving disease process, which is often associated
with a dismal outcome eventually requiring liver
transplantation.4,5
In conclusion, this case of HVOD after pancreas trans-
plantation with immunosuppressive therapy is the first re-
ported in the literature. The causative agent was presumed to
be tacrolimus since complete recovery was observed
after discontinuation of tacrolimus. Pancreas transplantationphysicians should raise the suspicion of HVOD when a
recipient presents with hepatomegaly, ascites, or jaundice.
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